Skip to main content
. 2024 Aug 20;15:1413233. doi: 10.3389/fimmu.2024.1413233

Figure 4.

Figure 4

Differences in the percentages of CD8 T-cell subpopulations in patients under treatment with omalizumab compared to HD and treated with NID. Percentages of (A) naïve, (B) central memory, (C) effector memory, and (D) effector CD8 T cells in peripheral blood of HD, NID and CSU patients under omalizumab treatment. CSU, chronic spontaneous urticaria; HD, healthy donors (n = 50); NID, non-immunomodulatory drugs (n = 27); OZB, omalizumab (n = 24).